Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial
Open Access
- 31 March 2021
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 42 (13), 1216-1227
- https://doi.org/10.1093/eurheartj/ehab094
Abstract
Mortality rates from chronic kidney disease (CKD) have increased in the last decade. In this pre-specified analysis of the DAPA-CKD trial, we determined the effects of dapagliflozin on cardiovascular and non-cardiovascular causes of death. DAPA-CKD was an international, randomized, placebo-controlled trial with a median of 2.4 years of follow-up. Eligible participants were adult patients with CKD, defined as a urinary albumin-to-creatinine ratio (UACR) 200–5000 mg/g and an estimated glomerular filtration rate (eGFR) 25–75 mL/min/1.73 m2. All-cause mortality was a key secondary endpoint. Cardiovascular and non-cardiovascular death was adjudicated by an independent clinical events committee. The DAPA-CKD trial randomized participants to dapagliflozin 10 mg/day (n = 2152) or placebo (n = 2152). The mean age was 62 years, 33% were women, the mean eGFR was 43.1 mL/min/1.73 m2, and the median UACR was 949 mg/g. During follow-up, 247 (5.7%) patients died, of whom 91 (36.8%) died due to cardiovascular causes, 102 (41.3%) due to non-cardiovascular causes, and in 54 (21.9%) patients, the cause of death was undetermined. The relative risk reduction for all-cause mortality with dapagliflozin (31%, hazard ratio [HR] [95% confidence interval (CI)] 0.69 [0.53, 0.88]; P = 0.003) was consistent across pre-specified subgroups. The effect on all-cause mortality was driven largely by a 46% relative risk reduction of non-cardiovascular death (HR [95% CI] 0.54 [0.36, 0.82]). Deaths due to infections and malignancies were the most frequently occurring causes of non-cardiovascular deaths and were reduced with dapagliflozin vs. placebo. In patients with CKD, dapagliflozin prolonged survival irrespective of baseline patient characteristics. The benefits were driven largely by reductions in non-cardiovascular death. Dapagliflozin prolonged survival irrespective of baseline patient characteristics, largely driven by reductions in non-CV death.Keywords
Funding Information
- AstraZeneca
This publication has 27 references indexed in Scilit:
- Dapagliflozin‐lowered blood glucose reduces respiratory Pseudomonas aeruginosa infection in diabetic miceBritish Journal of Pharmacology, 2017
- Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 DiabetesDiabetes Care, 2016
- Canagliflozin Slows Progression of Renal Function Decline Independently of Glycemic EffectsJournal of the American Society of Nephrology, 2016
- Association of Kidney Disease Measures with Cause-Specific Mortality: The Korean Heart StudyPLOS ONE, 2016
- Cause of Death in Patients with Reduced Kidney FunctionJournal of the American Society of Nephrology, 2015
- Cause of Death in Patients With Diabetic CKD Enrolled in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)American Journal of Kidney Diseases, 2015
- Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysisThe Lancet, 2015
- Chronic Kidney Disease and Risk of Death from InfectionAmerican Journal of Nephrology, 2011
- The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trialThe Lancet, 2011
- Problems With Proper Completion and Accuracy of the Cause-of-Death StatementArchives of Internal Medicine, 2001